Page 4 - Upfront Payment News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Spinal muscular atrophy, a leading genetic cause of infant deaths, prevents the body from producing a protein necessary for neuromuscular development. Royalty Pharma said the agreement with PTC increases its ownership of the Evrysdi royalty from 43% to 81%, equating to a royalty of 6.5% to 13%. The company had in 2020 purchased about 43% of PTC's royalty interest in risdiplam for a one-time payment of $650 million.

Danish drugmaker Novo Nordisk said on Monday it would collaborate with U.S. tech firm Valo Health to discover and develop new treatments for cardiometabolic diseases using human data and artificial intelligence. Novo Nordisk said in a statement it will use Valo's platform and Valo will receive an upfront payment and a potential near-term milestone payment of $60 million. Valo is also eligible to receive milestone payments for up to 11 programmes, totalling up to $2.7 billion, plus research and development funding and potential royalty payments, Novo said.

AbbVie's decision to scrap the deal comes after it pulled the plug on an early-stage study in August last year that was testing lemzoparlimab in combination with two other drugs for treating two types of blood cancers, myelodysplastic syndrome and acute myelocytic leukemia. The deal termination will be effective Nov. 20 this year, and will not affect upfront and milestone payments of $200 million that the company has received from AbbVie, according to I-Mab. I-Mab said it will explore future dev

AbbVie's decision to scrap the deal comes after it pulled the plug on an early-stage study in August last year that was testing lemzoparlimab in combination with two other drugs for treating two types of blood cancers, myelodysplastic syndrome and acute myelocytic leukemia. The deal termination will be effective Nov. 20 this year, and will not affect upfront and milestone payments of $200 million that the company has received from AbbVie, according to I-Mab. I-Mab said it will explore future development opportunities with lemzoparlimab.

Form 20-F T Form 40-F □ As previously reported on a Form 6-K filed by BeyondSpring Inc. , Dalian Wanchunbulin Pharmaceuticals Ltd. , the Company's 58%-owned...